Your browser doesn't support javascript.
loading
Liver transplantation for pediatric patients with congenital heart disease: A single-center study in mainland China.
Li, Tingting; Wei, Xinzhe; Hu, Xiangyu; Ye, Xuying; Li, Chao; Li, Zhuqing; Li, Qi; Liu, Chunlei; Gao, Wei; Lu, Chengzhi.
Afiliação
  • Li T; The First Central Clinical School, Tianjin Medical University, Tianjin, China.
  • Wei X; Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Hu X; Pediatric Transplant Department, Tianjin First Central Hospital, Tianjin, China.
  • Ye X; The Key Subject of Tianjin First Central Hospital, Tianjin, China.
  • Li C; Ultrasound Department, Tianjin First Central Hospital, Tianjin, China.
  • Li Z; Department of Cardiology, Tianjin First Central Hospital, Tianjin, China.
  • Li Q; Department of Cardiology, Tianjin First Central Hospital, Tianjin, China.
  • Liu C; Department of Cardiology, Tianjin First Central Hospital, Tianjin, China.
  • Gao W; School of Medicine, Nankai University, Tianjin, China.
  • Lu C; School of Medicine, Nankai University, Tianjin, China.
Pediatr Transplant ; 28(1): e14598, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37947026
ABSTRACT

BACKGROUND:

Liver transplantation (LT) is a serious cardiovascular stressor for patients with end-stage liver disease (ESLD). Data on the effects of cardiovascular diseases on pediatric LT is limited. No study on LT for pediatric patients with ESLD combined with congenital heart disease (CHD) has been reported from mainland China.

METHODS:

A total of 1005 patients were included in this study. The Kaplan-Meier method with log-rank testing was used to evaluate survival outcomes between groups. Univariable and multivariable Cox regression models were used to determine the risk factors for patient and graft survival.

RESULTS:

The most common indication for LT was biliary atresia (BA 90.3%). The prevalence of CHD was 3.8% (38). 42 CHD were found in 38 patients. The incidence of death and graft loss was more common in the CHD group than in the no-CHD group (13.2% vs. 5.0%, p = .045 and 15.8% vs. 6.2%, p = .019, respectively). The 5-year patient survival and graft survival in the CHD group versus the no-CHD group was 86.8% versus 94.7% (log-rank p = .022) and 84.2% versus 93.5% (log-rank p = .015), respectively. No significant differences were observed in re-transplantation, hepatic artery thrombosis (HAT), and portal vein thrombosis (PVT). After adjusting for age, BMI, etiology of LT, and other confounding factors, we can still find that the presence of CHD was associated with patient and graft survival after LT.

CONCLUSION:

The presence of CHD was associated with higher mortality and lower graft survival after LT. If possible, the cardiac defects should be addressed prior to LT.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Trombose Venosa / Doença Hepática Terminal / Cardiopatias Congênitas / Hepatopatias Limite: Child / Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Trombose Venosa / Doença Hepática Terminal / Cardiopatias Congênitas / Hepatopatias Limite: Child / Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article